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than 15 days in medication coverage. Three statistical models
corresponding to the three measures of medication reﬁll persis-
tence were performed: Tobit model, logistic regression, and 
survival analysis. Control variables included demographic and
social economic information, health status, medication condi-
tions, health service utilization, and drug beneﬁt characteristics.
RESULTS: The study included 1549 members, 42.0% female,
mean age 55.7 years, with member cost-sharing of about $12
per 30 days supply. For every $1 increase in 30 day average cost-
sharing, total gap increased by 2.7% (transferred Tobit coefﬁ-
cient = 0.027, 95% CI = [0.011, 0.043], p = 0.001); the odds of
non-persistence (PDC < 80%) increased by 2.5% (OR = 1.025,
95% CI = [1.007, 1.042], p = 0.005); and the risk to have a gap
of more than 15 days increased by 1.7% (HR = 1.017, 95% CI
= [1.007, 1.027], p = 0.001). CONCLUSION: Prescription cost-
sharing was associated with a signiﬁcant and negative impact 
on medication reﬁll persistence after controlling for other con-
founders. It is important for health plans and self insured
employers to consider the implications of member contribution
on medication reﬁll persistence when making pharmacy beneﬁt
design decisions.
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OBJECTIVES: To evaluate the long-term health outcomes of
ACS patients taking clopidogrel and aspirin, either alone or 
in combination, within the California Medicaid population.
METHODS: A retrospective claims study was conducted for the
10-year period from 1995–2004. Patients were ≥19 years of age,
with ≥6 months of continuous eligibility prior to index date, and
≥1 month of continuous eligibility after index date. Patients hos-
pitalized with UA or NSTEMI were identiﬁed using ICD-9 codes
and divided into 3 subgroups: clopidogrel-only (CO), aspirin-
only (AO), and clopidogrel/aspirin (CA). Cox proportional-
hazard models were used to estimate hazard ratios (HR) for 
time to death, major bleeding events (MBE; ICD-9 codes
531.x1–535.x1), re-hospitalization, and revascularization with
covariate adjustment. The unadjusted time-to-event curves were
estimated using Kaplan-Meier (KM) techniques. RESULTS: The
UA/NSTEMI study population included 6448 patients. KM
curves showed no difference in time to MBE among the 3 groups.
With AO (n = 3738) serving as the baseline, HR for CA (n =
2071) was 1.05 (P = 0.65); HR for CO (n = 639) was 0.985 (P
= 0.93). The KM curves for CO and AO showed no difference
in time to death. However, HR for CA was 0.706 (P = 0.0030),
indicating that patients taking both drugs had a roughly 30%
lower risk of death compared with patients taking AO. In con-
trast, CA had a 50% higher risk of re-hospitalization (HR =
1.50, P < 0.0001) and revascularization (HR = 1.51, P < 0.0001)
than AO. No statistically signiﬁcant differences in risk were
found between CO and AO for re-hospitalization (HR = 0.80, P
= 0.18) or revascularization (HR = 1.18, P = 0.18). CONCLU-
SION: The results suggest patients taking clopidogrel or aspirin,
either alone or in combination, have similar long-term bleeding
risk. The combination of clopidogrel and aspirin may reduce the
risk of death compared with either drug alone. However, com-
bination therapy did not lead to a decrease in re-hospitalization
or revascularization compared with either drug alone.
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OBJECTIVES: On July 12, 2005 the Arkansas Medicaid
program implemented a prior approval policy for calcium
channel blockers (CCBs) in which Diltiazem ER, Dynacirc CR,
Nifedipine ER, XL, CC, CR, Norvasc, and Verapamil SR, SA,
were the preferred drugs. The objective of this study was to 
estimate the impact of this policy on CCB expenditures.
METHODS: This study utilized a time series panel design to
evaluate the impact of the policy using Arkansas Medicaid
administrative claims data obtained from January 2003 through
May 2006. Auto-Regressive Integrated Moving Average
(ARIMA) time series models were speciﬁed using monthly pre-
scription expenditures and utilization in the pre-policy period
(January 2003–June 2005) to forecast expenditures and utiliza-
tion in the post-policy period. The Medicaid payer perspective
was used and all prescription costs were calculated based on the
amount paid for each claim adjusted for product speciﬁc CMS
rebates. RESULTS: The average forecast expenditures for 
CCBs for August 2005–May 2006 was $426,706 (95%CI:
410,356–443,055) per month and observed expenditures were
$331,547 indicating that the policy change was associated with
a 22% reduction in CCB expenditures or $95,159 (95%CI:
78,809–111,508) per month. The average monthly savings were
$114,521 prior to January 2006 and were $75,796 after
Medicare dual eligibles began receiving Part-D beneﬁts. Non-sig-
niﬁcant reductions in CCB utilization were observed in the initial
4 months following the policy, however by May 2006, 4065
(95%CI: 3811–4319) recipients were expected to be taking
CCBs but only 3046 actually had a CCB prescription ﬁlled.
CONCLUSION: This CCB preferred drug list resulted in sub-
stantial savings of approximately $100,000 per month. Some of
the savings appear to be a result of reduced utilization of CCBs
which may indicate that other cardiovascular drugs may have
been used in place of CCBs or CCB discontinuation.
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OBJECTIVES: The Medicare Modernization Act explicitly ruled
out the possibility that the federal government could directly
negotiate drug prices as an effective way to contain costs for Part
D. Recent changes in the leadership of congress have led to a
reemergence of debate on this issue. Taking a societal perspec-
tive, we sought to quantify how much money for prescription
drugs could be saved among the elderly if prices nationwide were
equivalent to 2006 Federal Supply Schedule (FSS) prices for
several of the top selling prescription drug classes. METHODS:
Cross-sectional analysis of the nationally representative Medical
Expenditure Panel Survey, 2004. Adults > 64 years who ﬁlled a
prescription for any drug within the following classes were
included: Angiotensin Receptor Blockers, ACE inhibitors, HMG-
CoA Reductase Inhibitors (Statins), Proton Pump Inhibitors,
Non-Steroidal Anti-inﬂammatory, Histamine-2 Receptor Antag-
onists, Dihydropyridine Calcium Channel Blockers, and Steroid
Inhalers (n = 2198 individuals). The average price/pill for each
